Mitra, A.V.
Bancroft, E.K.
Barbachano, Y.
Page, E.C.
Foster, C.S.
Jameson, C.
Mitchell, G.
Lindeman, G.J.
Stapleton, A.
Suthers, G.
Evans, D.G.
Cruger, D.
Blanco, I.
Mercer, C.
Kirk, J.
Maehle, L.
Hodgson, S.
Walker, L.
Izatt, L.
Douglas, F.
Tucker, K.
Dorkins, H.
Clowes, V.
Male, A.
Donaldson, A.
Brewer, C.
Doherty, R.
Bulman, B.
Osther, P.J.
Salinas, M.
Eccles, D.
Axcrona, K.
Jobson, I.
Newcombe, B.
Cybulski, C.
Rubinstein, W.S.
Buys, S.
Townshend, S.
Friedman, E.
Domchek, S.
Ramon Y Cajal, T.
Spigelman, A.
Teo, S.H.
Nicolai, N.
Aaronson, N.
Ardern-Jones, A.
Bangma, C.
Dearnaley, D.
Eyfjord, J.
Falconer, A.
Grönberg, H.
Hamdy, F.
Johannsson, O.
Khoo, V.
Kote-Jarai, Z.
Lilja, H.
Lubinski, J.
Melia, J.
Moynihan, C.
Peock, S.
Rennert, G.
Schröder, F.
Sibley, P.
Suri, M.
Wilson, P.
Bignon, Y.J.
Strom, S.
Tischkowitz, M.
Liljegren, A.
Ilencikova, D.
Abele, A.
Kyriacou, K.
van Asperen, C.
Kiemeney, L.
IMPACT Study Collaborators,
Easton, D.F.
Eeles, R.A.
(2011). Targeted prostate cancer screening in men with mutations in BRCA1 and BRCA2 detects aggressive prostate cancer: preliminary analysis of the results of the IMPACT study. Bju int,
Vol.107
(1),
pp. 28-39.
show abstract
full text
OBJECTIVE: To evaluate the role of targeted prostate cancer screening in men with BRCA1 or BRCA2 mutations, an international study, IMPACT (Identification of Men with a genetic predisposition to ProstAte Cancer: Targeted screening in BRCA1/2 mutation carriers and controls), was established. This is the first multicentre screening study targeted at men with a known genetic predisposition to prostate cancer. A preliminary analysis of the data is reported. PATIENTS AND METHODS: Men aged 40-69 years from families with BRCA1 or BRCA2 mutations were offered annual prostate specific antigen (PSA) testing, and those with PSA > 3 ng/mL, were offered a prostate biopsy. Controls were men age-matched (± 5 years) who were negative for the familial mutation. RESULTS: In total, 300 men were recruited (205 mutation carriers; 89 BRCA1, 116 BRCA2 and 95 controls) over 33 months. At the baseline screen (year 1), 7.0% (21/300) underwent a prostate biopsy. Prostate cancer was diagnosed in ten individuals, a prevalence of 3.3%. The positive predictive value of PSA screening in this cohort was 47·6% (10/21). One prostate cancer was diagnosed at year 2. Of the 11 prostate cancers diagnosed, nine were in mutation carriers, two in controls, and eight were clinically significant. CONCLUSIONS: The present study shows that the positive predictive value of PSA screening in BRCA mutation carriers is high and that screening detects clinically significant prostate cancer. These results support the rationale for continued screening in such men..
Kote-Jarai, Z.
Olama, A.A.
Giles, G.G.
Severi, G.
Schleutker, J.
Weischer, M.
Campa, D.
Riboli, E.
Key, T.
Gronberg, H.
Hunter, D.J.
Kraft, P.
Thun, M.J.
Ingles, S.
Chanock, S.
Albanes, D.
Hayes, R.B.
Neal, D.E.
Hamdy, F.C.
Donovan, J.L.
Pharoah, P.
Schumacher, F.
Henderson, B.E.
Stanford, J.L.
Ostrander, E.A.
Sorensen, K.D.
Dörk, T.
Andriole, G.
Dickinson, J.L.
Cybulski, C.
Lubinski, J.
Spurdle, A.
Clements, J.A.
Chambers, S.
Aitken, J.
Gardiner, R.A.
Thibodeau, S.N.
Schaid, D.
John, E.M.
Maier, C.
Vogel, W.
Cooney, K.A.
Park, J.Y.
Cannon-Albright, L.
Brenner, H.
Habuchi, T.
Zhang, H.-.
Lu, Y.-.
Kaneva, R.
Muir, K.
Benlloch, S.
Leongamornlert, D.A.
Saunders, E.J.
Tymrakiewicz, M.
Mahmud, N.
Guy, M.
O'Brien, L.T.
Wilkinson, R.A.
Hall, A.L.
Sawyer, E.J.
Dadaev, T.
Morrison, J.
Dearnaley, D.P.
Horwich, A.
Huddart, R.A.
Khoo, V.S.
Parker, C.C.
Van As, N.
Woodhouse, C.J.
Thompson, A.
Christmas, T.
Ogden, C.
Cooper, C.S.
Lophatonanon, A.
Southey, M.C.
Hopper, J.L.
English, D.R.
Wahlfors, T.
Tammela, T.L.
Klarskov, P.
Nordestgaard, B.G.
Røder, M.A.
Tybjærg-Hansen, A.
Bojesen, S.E.
Travis, R.
Canzian, F.
Kaaks, R.
Wiklund, F.
Aly, M.
Lindstrom, S.
Diver, W.R.
Gapstur, S.
Stern, M.C.
Corral, R.
Virtamo, J.
Cox, A.
Haiman, C.A.
Le Marchand, L.
Fitzgerald, L.
Kolb, S.
Kwon, E.M.
Karyadi, D.M.
Orntoft, T.F.
Borre, M.
Meyer, A.
Serth, J.
Yeager, M.
Berndt, S.I.
Marthick, J.R.
Patterson, B.
Wokolorczyk, D.
Batra, J.
Lose, F.
McDonnell, S.K.
Joshi, A.D.
Shahabi, A.
Rinckleb, A.E.
Ray, A.
Sellers, T.A.
Lin, H.-.
Stephenson, R.A.
Farnham, J.
Muller, H.
Rothenbacher, D.
Tsuchiya, N.
Narita, S.
Cao, G.-.
Slavov, C.
Mitev, V.
Easton, D.F.
Eeles, R.A.
UK Genetic Prostate Cancer Study Collaborators/British Association of Urological Surgeons' Section of Oncology,
UK ProtecT Study Collaborators, The Australian Prostate Cancer BioResource,
PRACTICAL Consortium,
(2011). Seven prostate cancer susceptibility loci identified by a multi-stage genome-wide association study. Nat genet,
Vol.43
(8),
pp. 785-791.
show abstract
Prostate cancer (PrCa) is the most frequently diagnosed male cancer in developed countries. We conducted a multi-stage genome-wide association study for PrCa and previously reported the results of the first two stages, which identified 16 PrCa susceptibility loci. We report here the results of stage 3, in which we evaluated 1,536 SNPs in 4,574 individuals with prostate cancer (cases) and 4,164 controls. We followed up ten new association signals through genotyping in 51,311 samples in 30 studies from the Prostate Cancer Association Group to Investigate Cancer Associated Alterations in the Genome (PRACTICAL) consortium. In addition to replicating previously reported loci, we identified seven new prostate cancer susceptibility loci on chromosomes 2p11, 3q23, 3q26, 5p12, 6p21, 12q13 and Xq12 (P = 4.0 × 10(-8) to P = 2.7 × 10(-24)). We also identified a SNP in TERT more strongly associated with PrCa than that previously reported. More than 40 PrCa susceptibility loci, explaining ∼25% of the familial risk in this disease, have now been identified..
Edwards, S.M.
Evans, D.G.
Hope, Q.
Norman, A.R.
Barbachano, Y.
Bullock, S.
Kote-Jarai, Z.
Meitz, J.
Falconer, A.
Osin, P.
Fisher, C.
Guy, M.
Jhavar, S.G.
Hall, A.L.
O'Brien, L.T.
Gehr-Swain, B.N.
Wilkinson, R.A.
Forrest, M.S.
Dearnaley, D.P.
Ardern-Jones, A.T.
Page, E.C.
Easton, D.F.
Eeles, R.A.
UK Genetic Prostate Cancer Study Collaborators and BAUS Section of Oncology,
(2010). Prostate cancer in BRCA2 germline mutation carriers is associated with poorer prognosis. Br j cancer,
Vol.103
(6),
pp. 918-924.
show abstract
BACKGROUND: The germline BRCA2 mutation is associated with increased prostate cancer (PrCa) risk. We have assessed survival in young PrCa cases with a germline mutation in BRCA2 and investigated loss of heterozygosity at BRCA2 in their tumours. METHODS: Two cohorts were compared: one was a group with young-onset PrCa, tested for germline BRCA2 mutations (6 of 263 cases had a germline BRAC2 mutation), and the second was a validation set consisting of a clinical set from Manchester of known BRCA2 mutuation carriers (15 cases) with PrCa. Survival data were compared with a control series of patients in a single clinic as determined by Kaplan-Meier estimates. Loss of heterozygosity was tested for in the DNA of tumour tissue of the young-onset group by typing four microsatellite markers that flanked the BRCA2 gene, followed by sequencing. RESULTS: Median survival of all PrCa cases with a germline BRCA2 mutation was shorter at 4.8 years than was survival in controls at 8.5 years (P=0.002). Loss of heterozygosity was found in the majority of tumours of BRCA2 mutation carriers. Multivariate analysis confirmed that the poorer survival of PrCa in BRCA2 mutation carriers is associated with the germline BRCA2 mutation per se. CONCLUSION: BRCA2 germline mutation is an independent prognostic factor for survival in PrCa. Such patients should not be managed with active surveillance as they have more aggressive disease..
Al Olama, A.A.
Kote-Jarai, Z.
Giles, G.G.
Guy, M.
Morrison, J.
Severi, G.
Leongamornlert, D.A.
Tymrakiewicz, M.
Jhavar, S.
Saunders, E.
Hopper, J.L.
Southey, M.C.
Muir, K.R.
English, D.R.
Dearnaley, D.P.
Ardern-Jones, A.T.
Hall, A.L.
O'Brien, L.T.
Wilkinson, R.A.
Sawyer, E.
Lophatananon, A.
UK Genetic Prostate Cancer Study Collaborators/British Association of Urological Surgeons' Section of Oncology,
UK Prostate testing for cancer and Treatment study (ProtecT Study) Collaborators,
Horwich, A.
Huddart, R.A.
Khoo, V.S.
Parker, C.C.
Woodhouse, C.J.
Thompson, A.
Christmas, T.
Ogden, C.
Cooper, C.
Donovan, J.L.
Hamdy, F.C.
Neal, D.E.
Eeles, R.A.
Easton, D.F.
(2009). Multiple loci on 8q24 associated with prostate cancer susceptibility. Nat genet,
Vol.41
(10),
pp. 1058-1060.
show abstract
Previous studies have identified multiple loci on 8q24 associated with prostate cancer risk. We performed a comprehensive analysis of SNP associations across 8q24 by genotyping tag SNPs in 5,504 prostate cancer cases and 5,834 controls. We confirmed associations at three previously reported loci and identified additional loci in two other linkage disequilibrium blocks (rs1006908: per-allele OR = 0.87, P = 7.9 x 10(-8); rs620861: OR = 0.90, P = 4.8 x 10(-8)). Eight SNPs in five linkage disequilibrium blocks were independently associated with prostate cancer susceptibility..
Eeles, R.A.
Kote-Jarai, Z.
Al Olama, A.A.
Giles, G.G.
Guy, M.
Severi, G.
Muir, K.
Hopper, J.L.
Henderson, B.E.
Haiman, C.A.
Schleutker, J.
Hamdy, F.C.
Neal, D.E.
Donovan, J.L.
Stanford, J.L.
Ostrander, E.A.
Ingles, S.A.
John, E.M.
Thibodeau, S.N.
Schaid, D.
Park, J.Y.
Spurdle, A.
Clements, J.
Dickinson, J.L.
Maier, C.
Vogel, W.
Dörk, T.
Rebbeck, T.R.
Cooney, K.A.
Cannon-Albright, L.
Chappuis, P.O.
Hutter, P.
Zeegers, M.
Kaneva, R.
Zhang, H.-.
Lu, Y.-.
Foulkes, W.D.
English, D.R.
Leongamornlert, D.A.
Tymrakiewicz, M.
Morrison, J.
Ardern-Jones, A.T.
Hall, A.L.
O'Brien, L.T.
Wilkinson, R.A.
Saunders, E.J.
Page, E.C.
Sawyer, E.J.
Edwards, S.M.
Dearnaley, D.P.
Horwich, A.
Huddart, R.A.
Khoo, V.S.
Parker, C.C.
Van As, N.
Woodhouse, C.J.
Thompson, A.
Christmas, T.
Ogden, C.
Cooper, C.S.
Southey, M.C.
Lophatananon, A.
Liu, J.-.
Kolonel, L.N.
Le Marchand, L.
Wahlfors, T.
Tammela, T.L.
Auvinen, A.
Lewis, S.J.
Cox, A.
FitzGerald, L.M.
Koopmeiners, J.S.
Karyadi, D.M.
Kwon, E.M.
Stern, M.C.
Corral, R.
Joshi, A.D.
Shahabi, A.
McDonnell, S.K.
Sellers, T.A.
Pow-Sang, J.
Chambers, S.
Aitken, J.
Gardiner, R.A.
Batra, J.
Kedda, M.A.
Lose, F.
Polanowski, A.
Patterson, B.
Serth, J.
Meyer, A.
Luedeke, M.
Stefflova, K.
Ray, A.M.
Lange, E.M.
Farnham, J.
Khan, H.
Slavov, C.
Mitkova, A.
Cao, G.
UK Genetic Prostate Cancer Study Collaborators/British Association of Urological Surgeons' Section of Oncology,
UK ProtecT Study Collaborators,
PRACTICAL Consortium,
Easton, D.F.
(2009). Identification of seven new prostate cancer susceptibility loci through a genome-wide association study. Nat genet,
Vol.41
(10),
pp. 1116-1121.
show abstract
Prostate cancer (PrCa) is the most frequently diagnosed cancer in males in developed countries. To identify common PrCa susceptibility alleles, we previously conducted a genome-wide association study in which 541,129 SNPs were genotyped in 1,854 PrCa cases with clinically detected disease and in 1,894 controls. We have now extended the study to evaluate promising associations in a second stage in which we genotyped 43,671 SNPs in 3,650 PrCa cases and 3,940 controls and in a third stage involving an additional 16,229 cases and 14,821 controls from 21 studies. In addition to replicating previous associations, we identified seven new prostate cancer susceptibility loci on chromosomes 2, 4, 8, 11 and 22 (with P = 1.6 x 10(-8) to P = 2.7 x 10(-33))..
Eeles, R.A.
Kote-Jarai, Z.
Giles, G.G.
Olama, A.A.
Guy, M.
Jugurnauth, S.K.
Mulholland, S.
Leongamornlert, D.A.
Edwards, S.M.
Morrison, J.
Field, H.I.
Southey, M.C.
Severi, G.
Donovan, J.L.
Hamdy, F.C.
Dearnaley, D.P.
Muir, K.R.
Smith, C.
Bagnato, M.
Ardern-Jones, A.T.
Hall, A.L.
O'Brien, L.T.
Gehr-Swain, B.N.
Wilkinson, R.A.
Cox, A.
Lewis, S.
Brown, P.M.
Jhavar, S.G.
Tymrakiewicz, M.
Lophatananon, A.
Bryant, S.L.
UK Genetic Prostate Cancer Study Collaborators,
British Association of Urological Surgeons' Section of Oncology,
UK ProtecT Study Collaborators,
Horwich, A.
Huddart, R.A.
Khoo, V.S.
Parker, C.C.
Woodhouse, C.J.
Thompson, A.
Christmas, T.
Ogden, C.
Fisher, C.
Jamieson, C.
Cooper, C.S.
English, D.R.
Hopper, J.L.
Neal, D.E.
Easton, D.F.
(2008). Multiple newly identified loci associated with prostate cancer susceptibility. Nat genet,
Vol.40
(3),
pp. 316-321.
show abstract
Prostate cancer is the most common cancer affecting males in developed countries. It shows consistent evidence of familial aggregation, but the causes of this aggregation are mostly unknown. To identify common alleles associated with prostate cancer risk, we conducted a genome-wide association study (GWAS) using blood DNA samples from 1,854 individuals with clinically detected prostate cancer diagnosed at